Novasep moves eravacycline API to commercial-scale production

Novasep has won a contract to make commercial supplies of the API eravacycline, a next-generation infection fighter.

French CDMO Novasep, which has been making clinical supplies for a new-generation antibiotic being developed by U.S.-based Tetraphase Pharmaceuticals, will now start production for a potential commercial launch next year.

Novasep said it will continue to manufacture eravacycline at its facility in Chasse-sur-Rhône, France, where it has produced the clinical supply of the API since 2014. Eravacycline is a novel, fully synthetic tetracycline antibiotic under development for the treatment of life-threatening infections, including those caused by multidrug-resistant Gram-negative bacteria.

In its third-quarter report last month, Watertown, Massachusetts-based Tetraphase said that it had completed a phase 3 clinical trial which it will use along with data from an earlier trial for its NDA to treat complicated intra-abdominal infections and complicated urinary tract infections. It said it expects to file the NDA in the first quarter of 2018.

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

RELATED: Tetraphase shares tank as FDA demands new antibiotic PhIII trial

The FDA told Tetraphase in May 2016 that it would need further clinical data before it could consider approving eravacycline. Tetraphase has also submitted a Marketing Authorisation Application in Europe for the same use of eravacycline.  

Suggested Articles

With a slate of vaccine authorizations on the horizon, vaccine execs from a trio of leading shot makers are looking at distribution hurdles ahead.

News of an FDA plant inspection for a Macrogenics drug boosted investor confidence in BMS' ability to meet its year-end deadline for liso-cel.

Pfizer is pushing back on a Thursday report claiming it suddenly revised its COVID-19 vaccine targets for 2020, saying it announced that last month.